cGMP-dependent protein kinase 1 (Prkg1), mouse, recombinant

Organism: Mus musculus (Mouse). Source: E.coli. Expression Region: 2-671aa. Protein Length: Full Length of Mature Protein. Tag Info: N-terminal 10xHis-tagged and C-terminal Myc-tagged. Target Protein Sequence: SELEEDFAKI LMLKEERIKE LEKRLSEKEE EIQELKRKLH KCQSVLPVPS THIGPRTTRA QGISAEPQTY RSFHDLRQAF RKFTKSERSK DLIKEAILDN DFMKNLELSQ IQEIVDCMYP VEYGKDSCII KEGDVGSLVY VMEDGKVEVT KEGVKLCTMG PGKVFGELAI LYNCTRTATV KTLVNVKLWA IDRQCFQTIM MRTGLIKHTE YMEFLKSVPT FQSLPDEILS KLADVLEETH YENGEYIIRQ GARGDTFFII SKGQVNVTRE DSPSEDPVFL RTLGKGDWFG EKALQGEDVR TANVIAAEAV TCLVIDRDSF KHLIGGLDDV SNKAYEDAEA KAKYEAEAAF FANLKLSDFN IIDTLGVGGF GRVELVQLKS EESKTFAMKI LKKRHIVDTR QQEHIRSEKQ IMQGAHSDFI VRLYRTFKDS KYLYMLMEAC LGGELWTILR DRGSFEDSTT RFYTACVVEA FAYLHSKGII YRDLKPENLI LDHRGYAKLV DFGFAKKIGF GKKTWTFCGT PEYVAPEIIL NKGHDISADY WSLGILMYEL LTGSPPFSGP DPMKTYNIIL RGIDMIEFPK KIAKNAANLI KKLCRDNPSE RLGNLKNGVK DIQKHKWFEG FNWEGLRKGT LTPPIIPSVA SPTDTSNFDS FPEDSDEPPP DDNSGWDIDF. Purity: Greater than 90% as determined by SDS-PAGE. Endotoxin: Not test. Biological Activity: n/a. Form: Liquid or Lyophilized powder. Buffer: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20 °C/-80 °C. Our default final concentration of glycerol is 50%. Customers could use it as reference. Storage: The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20 °C/-80 °C. The shelf life of lyophilized form is 12 months at -20 °C/-80 °C. Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4 °C for up to one week. Relevance: Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation, decreasing contraction, controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle. Reference: "cGMP-dependent protein kinase type I is implicated in the regulation of the timing and quality of sleep and wakefulness." Langmesser S., Franken P., Feil S., Emmenegger Y., Albrecht U., Feil R. PLoS ONE 4:E4238-E4238(2009). Function: nan